SCHEMBL26088343

SCHEMBL26088343

CC(C(=O)N1CCN(c2cccc(Cl)c2)c2ccccc21)N1CCN(C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 1/20 0.47
▸ ATM Q13315 1/20 0.44
▸ DRD2 P14416 2/20 0.43
▸ DRD3 P35462 2/20 0.43
▸ KCNH2 Q12809 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ SIGMAR1 Q99720 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ CHRNA1 P02708 1/20 0.41
▸ CHRNG P07510 1/20 0.41
▸ CHRNB1 P11230 1/20 0.41
▸ CHRNB2 P17787 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ CHRNB4 P30926 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30378972 1.00 DRD4 (0.47) DRD4ATMDRD2DRD3KCNH2
SCHEMBL30910083 0.91 CHRNA1 (0.51) DRD4ATMDRD2DRD3KCNH2
SCHEMBL26090886 0.91 CHRNA1 (0.51) DRD4ATMDRD2DRD3KCNH2
SCHEMBL30378570 0.89 DRD4 (0.54) DRD4ATMDRD3KCNH2MEN1
SCHEMBL26088333 0.89 DRD4 (0.54) DRD4ATMDRD3KCNH2MEN1
SCHEMBL30379637 0.88 KMT2A (0.47) DRD4ATMMEN1KMT2AKDM4E
SCHEMBL26089655 0.88 KMT2A (0.47) DRD4ATMMEN1KMT2AKDM4E
SCHEMBL30378955 0.85 SMN1; SMN2 (0.49) DRD4ATMMEN1KMT2AKDM4E
SCHEMBL26090692 0.85 SMN1; SMN2 (0.49) DRD4ATMMEN1KMT2AKDM4E
SCHEMBL30910072 0.82 KMT2A (0.47) DRD4ATMMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN claimed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN disclosed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 DRD4 3728/4885ATM 2554/4885DRD2 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback